Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Recursion Pharmaceuticals, Inc. RXRX
$5.19
-$0.21 (-3.98%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1059592520.00000000
-
week52high
14.18
-
week52low
4.54
-
Revenue
39681000
-
P/E TTM
-4
-
Beta
-0.39323100
-
EPS
-1.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | 11 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| Goldman Sachs | Neutral | Neutral | 12 мая 2022 г. |
| B of A Securities | Neutral | Buy | 18 апр 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мар 2022 г. |
| Keybanc | Overweight | 16 сент 2022 г. | |
| SVB Leerink | Market Perform | Market Perform | 25 окт 2022 г. |
| Goldman Sachs | Neutral | Neutral | 09 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gibson Christopher | D | 125875 | 1000 | 02 февр 2023 г. |
| Gibson Christopher | D | 529000 | 1000 | 02 февр 2023 г. |
| Gibson Christopher | D | 539500 | 500 | 02 февр 2023 г. |
| Gibson Christopher | D | 6640334 | 18500 | 02 февр 2023 г. |
| Gibson Christopher | A | 1000 | 1000 | 02 февр 2023 г. |
| Gibson Christopher | D | 0 | 1000 | 02 февр 2023 г. |
| Gibson Christopher | A | 500 | 500 | 02 февр 2023 г. |
| Gibson Christopher | D | 942273 | 18500 | 02 февр 2023 г. |
| Gibson Christopher | A | 960773 | 18500 | 02 февр 2023 г. |
| Virani Shafique | A | 212507 | 212507 | 01 февр 2023 г. |
Новостная лента
Recursion to Participate in Upcoming Investor Conference
PRNewsWire
01 февр 2023 г. в 08:01
SALT LAKE CITY , Feb. 1, 2023 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference: SVB Securities Global Biopharma Conference — February 14 through February 16, 2023 About Recursion Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets.
Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' Now
Zacks Investment Research
27 янв 2023 г. в 11:17
After losing some value lately, a hammer chart pattern has been formed for Recursion Pharmaceuticals (RXRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
25 янв 2023 г. в 13:32
Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%
Zacks Investment Research
25 янв 2023 г. в 11:18
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recursion to Participate in Upcoming Investor Conferences
PRNewsWire
20 дек 2022 г. в 07:55
SALT LAKE CITY , Dec. 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: 41st Annual J.P. Morgan Healthcare Conference — January 9 through January 12, 2023 25th Annual Needham Growth Conference — January 10 through January 12, 2023 About Recursion Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology.